Indications for: LAMPIT
Chagas disease (American Trypanosomiasis) caused by Trypanosoma cruzi in pediatric patients (birth to <18yrs of age and weighing ≥2.5kg).
Swallow whole or divide in half by hand; do not use a tablet splitting device. If unable to swallow, tabs may be dispersed in water and administered as a slurry. Give 3 times daily with food for 60 days. Total daily dose: <18yrs (<40kg): 10–20mg/kg; (≥40kg): 8–10mg/kg. Individual dose: <18yrs (<2.5kg): not established; (2.5–4.5kg): 15mg; (4.6–<9kg): 30mg; (9–<13kg): 45mg; (13–<18kg): 60mg; (18–<22kg): 75mg; (22–<27kg): 90mg; (27–<35kg): 120mg; (35–<41kg): 180mg; (41–<51kg): 120mg; (51–<71kg): 180mg; (71–<91kg): 240mg; (≥91kg): 300mg.
Consuming alcohol during treatment.
Discontinue at the 1st sign of serious hypersensitivity. History of brain injury, seizures, psychiatric disease, serious behavioral alterations, neurological disturbances, psychiatric drug reactions, porphyria: administer under close medical supervision. Monitor body weight every 14 days; dose adjustment may be needed. Renal or hepatic impairment. Embryo-fetal toxicity. Advise to use effective contraception during and for 6 months (females of reproductive potential) or for 3 months (males w. female partners to use condoms) after the last dose. Pregnancy: exclude status prior to initiation. Nursing mothers: monitor infants.
See Contraindications. Potentiated by alcohol.
Vomiting, abdominal pain, headache, decreased appetite, nausea, pyrexia, rash; worsening of neurological and psychiatric conditions, hypersensitivity, weight loss, porphyria; potential for genotoxicity and carcinogenicity.
Renal (~44% and 27% under fed and fasted conditions, respectively). Half-life: 2.4–3.6 hours.
Generic Drug Availability: